0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News & Perspectives |

Studies May Not Provide Clear View of Antipsychotics

Bridget M. Kuehn
JAMA. 2012;307(15):1572. doi:10.1001/jama.2012.499.
Text Size: A A A
Published online

Extract

According to a recent analysis, the literature on atypical antipsychotic medications doesn't significantly inflate their overall effectiveness for the treatment of schizophrenia. Still, some negative studies and conclusions regarding the drugs' safety and efficacy have not been published, leaving clinicians with an incomplete picture of the drugs in this class.

There is evidence that clinical trial sponsors and researchers may avoid submitting for publication studies that have negative findings. Less commonly, some journals may hesitate to publish trials with negative results. Such bias can skew the evidence base so that an intervention appears more effective than it is. To assess whether such bias exists in the evidence base supporting antipsychotic medications, Erick H. Turner, MD, of the Oregon Health & Science University in Portland, and his colleagues looked at studies examining atypical antipsychotic drugs for the treatment of schizophrenia or schizoaffective disorder. The researchers compared the published studies with those that had been submitted to the US Food and Drug Administration (FDA) to gain approval to market the drugs for these indications (Turner EH et al. PLoS Med. 2012;9[3]:e1001189).

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Using the Guide—Part 8

brightcove.createExperiences();